source stringlengths 2 222 | date stringlengths 19 19 | url stringlengths 22 853 ⌀ | text stringlengths 0 10k ⌀ | title stringlengths 0 701 | context_id stringlengths 1 9 | document_id stringclasses 2
values | document_type stringclasses 2
values |
|---|---|---|---|---|---|---|---|
The Motley Fool | 2021-12-14 07:45:00 | https://www.fool.com/investing/2021/12/14/2-warren-buffett-dividend-stocks-to-buy-right-now/ | AbbVie and Royalty Pharma should be on every dividend investor's radar right now. | 2 Warren Buffett Dividend Stocks to Buy Right Now | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-12-14 04:57:27 | https://seekingalpha.com/article/4475084-springworks-swtx-stock-several-partnerships-solid-drug-pipeline | SpringWorks Is A Biotech To Watch With Several Partnerships And Solid Drug Pipeline | SpringWorks Is A Biotech To Watch With Several Partnerships And Solid Drug Pipeline | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
CNBC Television | 2021-12-13 13:50:57 | https://www.youtube.com/watch?v=G0cXFforUdQ | Kevin Mahn, Hennion & Walsh Asset Management president and CIO, joins 'The Exchange' to discuss what he considers to be the best inflation hedge. Mahn picks stocks he believes are best for dividend yields in today's inflation environment. | Dividend-paying stocks are the best inflation hedge, says Hennion & Walsh's Kevin Mahn | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-12-13 13:50:14 | https://www.zacks.com/stock/news/1838700/springworks-swtx-abbvie-unite-for-multiple-myeloma-drug | SpringWorks Therapeutics (SWTX) collaborates with AbbVie (ABBV) to evaluate the combination of nirogacestat with AbbVie's ABBV-383 for relapsed or refractory multiple myeloma. | SpringWorks (SWTX) & AbbVie Unite for Multiple Myeloma Drug | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-12-11 10:15:00 | https://www.fool.com/investing/2021/12/11/3-best-dividend-stocks-that-wall-street-is-sleepin/ | Don't let the market's apparent disinterest fool you into thinking that's a reflection of their value. | 3 Best Dividend Stocks That Wall Street Is Sleeping On | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2021-12-10 09:24:23 | https://www.benzinga.com/general/biotech/21/12/24544331/abbvie-springworks-join-forces-to-conduct-multiple-myeloma-combo-therapy-trial | SpringWorks Therapeutics Inc (NASDAQ: SWTX) entered into a clinical trial collaboration agreement with AbbVie Inc (NYSE: ABBV) to evaluate SpringWorks' nirogacestat combination with ABBV-383 in relapsed or refractory multiple myeloma. Gamma secretase inhibition helps prevent the cleavage and shedding of BCMA from the s... | AbbVie, SpringWorks Join Forces To Conduct Multiple Myeloma Combo Therapy Trial | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Pulse2 | 2021-12-09 22:43:24 | https://pulse2.com/abbvie-stock-nyse-abbv-165-price-target-from-wells-fargo/ | The shares of AbbVie Inc (NYSE: ABBV) have received a price target of $165 from Wells Fargo. These are the details. | AbbVie Stock (ABBV): $165 Price Target From Wells Fargo | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-12-09 19:08:21 | https://www.zacks.com/stock/news/1837655/abbvie-abbv-gains-as-market-dips-what-you-should-know | AbbVie (ABBV) closed the most recent trading day at $124.15, moving +1.87% from the previous trading session. | AbbVie (ABBV) Gains As Market Dips: What You Should Know | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Invezz | 2021-12-09 15:10:29 | https://invezz.com/news/2021/12/09/wells-fargo-sees-a-35-upside-in-this-pharma-stock/ | Shares of AbbVie Inc (NYSE: ABBV) took a massive hit in early September after losing exclusivity for Humira – its treatment for rheumatoid arthritis. The stock has since recovered completely, and Wells Fargo says there's more to come in the coming months. | Wells Fargo sees a 35% upside in this pharma stock | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
CNBC Television | 2021-12-09 14:13:02 | https://www.youtube.com/watch?v=uKzTZDlUsX0 | The "Halftime Report" traders debate Wells Fargo's bullish call on big pharma | Wells Fargo makes a bullish call on five big pharma stocks | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
24/7 Wall Street | 2021-12-09 07:35:10 | https://247wallst.com/healthcare-business/2021/12/09/biotech-has-been-crushed-5-stocks-to-buy-now-that-pay-big-dividends/ | We cover dividend stocks often at 24/7, as they provide investors with much better income streams than U.S. | Biotech Has Been Crushed: 5 Stocks to Buy Now That Pay Big Dividends | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-12-08 16:20:00 | https://seekingalpha.com/article/4474177-triple-your-retirement-income-with-these-6-percent-yielding-dividend-aristocrat-bargains | Fear has returned to Wall Street, with the market falling 4% in a matter of days as the Wall of Worry starts to take its toll. | Triple Your Retirement Income With These 6% Yielding Dividend Aristocrat Bargains | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Reuters | 2021-12-08 14:39:00 | https://www.reuters.com/business/healthcare-pharmaceuticals/jury-hear-final-arguments-ny-opioid-case-against-drugmakers-2021-12-08/ | AbbVie Inc agreed to pay $200 million to settle claims by New York that its Allergan unit helped fuel an epidemic of opioid addiction in the state, shortly before jurors heard closing arguments from remaining defendant Teva Pharmaceutical Industries Ltd in a trial that has lasted more than five months. | AbbVie settles New York opioid case for $200 million as trial winds down | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-12-07 13:54:05 | https://www.zacks.com/stock/news/1836485/abbvie-s-abbv-rinvoq-meets-goals-in-crohn-s-disease-study | AbbVie's (ABBV) Rinvoq achieves primary and key secondary endpoints in the first phase III induction study in patients with Crohn's Disease. | AbbVie's (ABBV) Rinvoq Meets Goals in Crohn's Disease Study | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-12-07 07:05:00 | https://seekingalpha.com/article/4473792-6-dividend-increases-expected-december-2021 | 6 Dividend Increases Expected In December 2021 | 6 Dividend Increases Expected In December 2021 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GuruFocus | 2021-12-06 17:55:45 | https://www.gurufocus.com/news/1589920/5-stocks-gurufocus-members-are-shunning-for-christmas | As of Monday, five stocks that GuruFocus members are shunning over the Christmas holiday are Tesla Inc. ( TSLA , Financial), Amazon.com Inc. ( AMZN , Financial), H&R Block Inc. ( HRB , Financial), Wells Fargo & Co. Inc. ( WFC , Financial) and AbbVie Inc. ( ABBV , Financial). | 5 Stocks GuruFocus Members Are Shunning for Christmas | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
CNBC Television | 2021-12-06 14:10:25 | https://www.youtube.com/watch?v=2AX14DOptwY | The "Halftime Report" traders give their top picks to watch for the second half. | Final Trades: Abbvie, CVS, Small caps & more | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2021-12-06 13:45:46 | https://www.benzinga.com/general/biotech/21/12/24464104/abbvies-upadacitinib-hits-primary-goal-in-induction-study-in-patients-with-crohns-disease | AbbVie Inc (NYSE: ABBV) announced topline results from U-EXCEED, a Phase 3 induction study, of upadacitinib (45 mg once daily) in Patients with Crohn's Disease. The data achieved both primary endpoints of clinical remission and endoscopic response at week 12. | AbbVie's Upadacitinib Hits Primary Goal In Induction Study In Patients With Crohn's Disease | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Stockmarketcom | 2021-12-06 13:32:01 | https://stockmarket.com/featured/5-biotech-stocks-to-watch-in-the-stock-market-today-2021-12-06 | Should investors be watching these biotech stocks with all the current focus on the Omicron Covid variant? | 5 Biotech Stocks To Watch In The Stock Market Today | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-12-06 07:56:18 | https://seekingalpha.com/article/4473580-dhs-yield-and-valuation-are-attractive-but-not-quality-and-performance | DHS: Yield And Valuation Are Attractive, But Not Quality And Performance | DHS: Yield And Valuation Are Attractive, But Not Quality And Performance | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-12-05 09:43:44 | https://seekingalpha.com/article/4473491-diversify-concentration-risks-of-several-pharma-companies | Roche is optimally diversified both in terms of geography and in terms of portfolio. Pfizer and Eli Lilly are also broadly diversified but are more U.S.-centric companies. AbbVie, but also Merck are currently over-reliant on a single drug but this appears to be priced into the stocks accordingly. | Diversify, Diversify - Concentration Risks Of Several Pharma Companies | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-12-02 14:07:03 | https://seekingalpha.com/article/4473068-abbvie-inc-abbv-presents-4th-annual-evercore-isi-virtual-healthconx-conference-transcript | AbbVie Inc. (ABBV) Presents at 4th Annual Evercore ISI Virtual HealthCONx Conference (Transcript) | AbbVie Inc. (ABBV) Presents at 4th Annual Evercore ISI Virtual HealthCONx Conference (Transcript) | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Market Watch | 2021-12-02 00:07:00 | https://www.marketwatch.com/story/brazen-is-probably-an-understatement-georgia-inmate-ran-multi-million-dollar-scam-from-prison-cell-posing-as-abbvie-employee-11638394803 | A Georgia prison inmate has been sentenced to seven additional years for running a multi-million dollar heavy equipment scam from behind bars, where he used contraband cell phones to pose as a purchasing agent for pharma company AbbVie Inc. | Financial Crime: ‘Brazen is probably an understatement': Georgia inmate ran multi-million dollar scam from prison cell posing as AbbVie employee | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-12-01 15:19:04 | https://www.zacks.com/stock/news/1834101/abbvie-abbv-files-for-skyrizi-to-treat-crohn-s-disease-in-eu | AbbVie (ABBV) submits a regulatory application in the European Union, seeking approval for risankizumab (Skyrizi) for the treatment of Crohn's disease. | AbbVie (ABBV) Files for Skyrizi to Treat Crohn's Disease in EU | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-12-01 10:45:00 | https://www.fool.com/investing/2021/12/01/2-ridiculously-cheap-dividend-stocks-to-buy-2022/ | AbbVie and ViacomCBS can provide investors a good mix of growth and dividend income. | 2 Ridiculously Cheap Dividend Stocks To Buy for 2022 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
24/7 Wall Street | 2021-12-01 07:28:10 | https://247wallst.com/healthcare-business/2021/12/01/5-health-care-dividend-aristocrats-to-buy-for-2022-as-yields-plunge-once-again/ | Just when you thought it was starting to look safer, yet another COVID-19 variant comes around. | 5 Health Care Dividend Aristocrats to Buy for 2022 as Yields Plunge Once Again | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
CNBC Television | 2021-11-29 13:19:07 | https://www.youtube.com/watch?v=p_-VI7ikq4w | Joe Terranova, senior managing director for Virtus Investment Partners, joins the 'Halftime Report' to discuss where to invest after Friday's sell-off. | Joe Terranova says the Street is underinvested in health care | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-11-28 00:30:22 | https://seekingalpha.com/article/4472136-abbvie-abbv-high-yielder-flood-with-cash | As an income investor, it can be difficult to find high-yield dividend stocks that can stuff your accounts with a growing amount of cash each year. AbbVie's payout ratio is positioned to improve from 41.1% this year to 40.3% next year despite its 8.5% dividend increase, which translates into a safe dividend with room t... | AbbVie: A High-Yielder That Can Flood You With Cash | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-11-23 18:37:01 | https://seekingalpha.com/article/4471640-1-to-buy-out-of-37-billionaire-holdings-in-november | Kiplinger Investing publishes opportune source-lists for investors online. Two recent billionaires stock-lists by Dan Burrows were published 6/1/21 and 9/9/21. 20 of the 37 billionaire-held stocks pay dividends. As of 11/21/21, the top-ten ranged 1.28%-5.77% by annual yield and ranged 18.52%-56.53% per broker-estimated... | 1 To Buy Out Of 37 Billionaire Holdings In November | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-11-23 17:07:30 | https://seekingalpha.com/article/4471622-abbvie-provides-optimal-balance-for-barbell-retirement-strategy | AbbVie offers an optimal combination of good current income, excellent financial safety, and strong secular support and growth. | AbbVie Provides Optimal Balance For Barbell Retirement Strategy | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2021-11-23 08:15:00 | https://www.prnewswire.com/news-releases/abbvie-to-present-at-the-evercore-isi-conference-301430236.html | NORTH CHICAGO, Ill., Nov. 23, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the 4th Annual Evercore ISI Virtual HealthCONx Conference on Thursday, December 2, 2021. | AbbVie to Present at the Evercore ISI Conference | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2021-11-23 08:00:00 | https://www.prnewswire.com/news-releases/abbvie-to-present-at-the-piper-sandler-healthcare-conference-301430238.html | NORTH CHICAGO, Ill., Nov. 23, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference on Wednesday, December 1, 2021. | AbbVie to Present at the Piper Sandler Healthcare Conference | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2021-11-22 06:09:31 | https://investorplace.com/2021/11/seven-high-yield-stock-gems-for-income-obsessed-investors/ | Investors seeking big payouts should consider these seven high-yield stocks from various sectors. They range from pharmaceuticals to REITs. | 7 High-Yield Stock Gems for Income-Obsessed Investors | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-11-21 08:00:00 | https://www.fool.com/investing/2021/11/21/should-you-buy-this-blue-chip-biotech-stock/ | AbbVie may be able to provide relief to the income investor struggling to find sanely valued stocks with safe dividends. | Should You Buy This Blue Chip Biotech Stock? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-11-21 05:52:00 | https://www.fool.com/investing/2021/11/21/4-top-dividend-stocks-id-buy-if-i-were-about-to-re/ | They're all solid companies with juicy dividends. | 4 Top Dividend Stocks I'd Buy If I Were About to Retire | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2021-11-19 08:00:00 | https://www.prnewswire.com/news-releases/allergan-aesthetics-to-present-data-from-its-leading-aesthetic-portfolio-at-the-2021-american-society-for-dermatologic-surgery-virtual-meeting-301426223.html | IRVINE, Calif., Nov. 19, 2021 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company, (NYSE: ABBV) today announced that it will present six abstracts from its leading portfolio of aesthetic treatments and products at the American Society for Dermatologic Surgery (ASDS) meeting taking place virtually November 19-21, 202... | Allergan Aesthetics To Present Data From Its Leading Aesthetic Portfolio At The 2021 American Society For Dermatologic Surgery Virtual Meeting | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GuruFocus | 2021-11-18 16:39:41 | https://www.gurufocus.com/news/1577886/look-to-big-pharma-for-healthy-dividends | Of the top nine members of Big Pharma with high dividend yields, Eli Lilly and Co. ( LLY , Financial) brings up the rear at 1.32%. But that hardly tells the full story. | Look to Big Pharma for Healthy Dividends | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Stockmarketcom | 2021-11-18 15:06:21 | https://stockmarket.com/featured/5-biotech-stocks-to-check-out-in-the-stock-market-now-2021-11-18 | Could these top biotech stocks be worth investing in for the long term? | 5 Biotech Stocks To Check Out In The Stock Market Now | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-11-18 14:33:04 | https://www.zacks.com/stock/news/1829571/abbvie-s-abbv-skyrizi-gets-nod-for-psoriatic-arthritis-in-eu | AbbVie (ABBV) secures approval in the EU for Skyrizi to treat adult patients with active psoriatic arthritis. | AbbVie's (ABBV) Skyrizi Gets Nod for Psoriatic Arthritis in EU | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
24/7 Wall Street | 2021-11-18 07:35:19 | https://247wallst.com/healthcare-business/2021/11/18/health-care-stocks-cheapest-in-30-years-5-with-big-dividends-to-buy-now/ | For years, one of the most dependable sectors, especially for more conservative investors, was health care, which includes the top pharmaceutical and biotech stocks. | Health Care Stocks Cheapest in 30 Years: 5 With Big Dividends to Buy Now | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-11-18 07:00:50 | https://seekingalpha.com/article/4470468-buy-five-high-yield-blue-chips-get-free-house | Home prices are up 20% in 2021 and Goldman Sachs estimates they'll rise 16% more in 2022. | Buy These 5 High-Yield Blue-Chips And Get A Free House | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2021-11-17 10:59:40 | https://www.benzinga.com/general/biotech/21/11/24147484/europe-approves-abbvies-skyrizi-for-second-indication | The European Commission (EC) has approved AbbVie Inc's (NYSE: ABBV) Skyrizi (risankizumab) 150 mg subcutaneous injection for psoriatic arthritis in adults. The approval covers Skyrizi alone or combined with methotrexate (MTX) for active psoriatic arthritis in adults who have had an inadequate response or have been into... | Europe Approves AbbVie's Skyrizi For Second Indication | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-11-17 07:50:00 | https://www.fool.com/investing/2021/11/17/1-dividend-stock-to-help-you-fight-inflation/ | We'll need this company's products long after the current inflation crisis ends. | 1 Dividend Stock to Help You Fight Inflation | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Reuters | 2021-11-16 07:04:00 | https://www.reuters.com/business/healthcare-pharmaceuticals/report-says-drugmakers-impose-unjustified-us-price-increases-spending-abbvie-2021-11-16/ | Drugmakers hiked U.S. prices on seven of the 10 costliest prescription drugs in 2020 without justification, increasing drug spending by $1.67 billion, a U.S. group that reviews the value of medicines said on Tuesday. | Report says drugmakers impose unjustified U.S. price increases; spending on AbbVie drug rises $1.4 billion | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-11-14 05:55:00 | https://www.fool.com/investing/2021/11/14/4-fantastic-dividend-stocks-to-buy-with-yields-of/ | Juicy yields. Solid businesses. | 4 Fantastic Dividend Stocks to Buy With Yields of 4% or More | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-11-13 06:46:00 | https://www.fool.com/investing/2021/11/13/these-dividend-stocks-pay-you-money-to-own-them/ | Dividend-paying stocks generate easy money -- delivered regularly, with no effort from you. | Believe It or Not, These Stocks Pay You to Own Them | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-11-09 15:22:00 | https://seekingalpha.com/article/4467503-dividend-income-summary-berts-october-2021-report | Dividend Income Summary: Bert's October 2021 Report | Dividend Income Summary: Bert's October 2021 Report | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2021-11-09 08:31:00 | https://www.prnewswire.com/news-releases/abbvie-to-present-new-long-term-analysis-evaluating-the-sustainability-of-response-to-rinvoq-upadacitinib-among-patients-with-rheumatoid-arthritis-301419810.html | NORTH CHICAGO, Ill., Nov. 9, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new results from a post-hoc analysis of the Phase 3 SELECT-BEYOND clinical trial evaluating RINVOQ® (upadacitinib; 15 mg, once daily) in patients with moderate to severe rheumatoid arthritis (RA) on stable background of conventional s... | AbbVie to Present New Long-term Analysis Evaluating the Sustainability of Response to RINVOQ® (Upadacitinib) Among Patients with Rheumatoid Arthritis | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2021-11-08 08:30:00 | https://www.prnewswire.com/news-releases/allergan-an-abbvie-company-to-present-new-data-from-its-leading-eye-care-portfolio-at-the-aao-american-academy-of-ophthalmology-2021-annual-meeting-301418026.html | NORTH CHICAGO, Ill., Nov. 8, 2021 /PRNewswire/ -- Allergan, an AbbVie (NYSE: ABBV) company, announced that it will present new pooled post-hoc analyses and patient-reported outcomes (PROs) of VUITYTM (pilocarpine HCl ophthalmic solution) 1.25%, newly approved by the FDA as the first and only eye drop to treat presbyopi... | Allergan, an AbbVie Company, to Present New Data from its Leading Eye Care Portfolio at the AAO (American Academy of Ophthalmology) 2021 Annual Meeting | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-11-07 05:52:00 | https://www.fool.com/investing/2021/11/07/investing-100000-in-these-dividend-stocks-could-gi/ | You should be able to count on these dividends over the long term. | Investing $100,000 in These Dividend Stocks Could Give You Nearly $6,000 in Steady Annual Income | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-11-06 09:00:00 | https://seekingalpha.com/article/4465404-near-perfect-portfolio-good-times-and-bad | No portfolio or strategy can be perfect. But can there be a strategy that can work well in a bull market, a bear market, or a stagnant market, generate a decent income, and conserve capital, all at the same time? We also want our strategy to avoid roller-coaster rides of index investing, have low volatility and limited... | The Near-Perfect Portfolio For The Good Times And Bad | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-11-05 16:37:25 | https://seekingalpha.com/article/4466177-112-s-and-p-high-yield-dividend-aristocrats-deliver-more-dog-per-dollar | "S&P High Yield Dividend Aristocrats index is designed to measure the performance of companies within the S&P Composite 1500 that have consistently increased dividends every year for at least 20 years." - spindices.com. | 112 S&P High Yield Dividend Aristocrats Deliver More Dog Per Dollar | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-11-05 08:00:00 | https://seekingalpha.com/article/4465863-abbvie-abbv-undervalued-dividend-growth-stock | AbbVie: Don't Worry Be Happy | AbbVie: Don't Worry Be Happy | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-11-03 14:50:00 | https://seekingalpha.com/article/4464985-dividend-income-summary-lannys-october-2021-summary | In October, we (my wife and I) received a total of $966.97 of dividend income. | Dividend Income Summary: Lanny's October 2021 Summary | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Stockmarketcom | 2021-11-03 13:00:36 | https://stockmarket.com/featured/best-stocks-to-buy-today-4-dividend-stocks-to-check-out-2021-11-03 | Dividend stocks could be worth paying attention to as the Federal Reserve may look to pull back its monetary support. | Best Stocks To Buy Today? 4 Dividend Stocks To Check Out | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-11-02 18:44:37 | https://seekingalpha.com/article/4464661-endo-win-in-california-but-equity-value-still-question | Endo: A Win In California But Equity Value Still A Question | Endo: A Win In California But Equity Value Still A Question | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-11-01 08:46:24 | https://seekingalpha.com/article/4464038-16-companies-to-announce-increases | Despite the economic uncertainty with supply chain issues and the potential for tax hikes, dividend increases in October were as expected. Double-digit boosts came from Amphenol, Brown & Brown, Lincoln Electric, Stepan Company, and Waste Connections. Biopharmaceutical company AbbVie also announced its newest increase i... | AbbVie Boosts Dividend In October; Emerson, 14 Others To Announce Increases In First Half Of November | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
24/7 Wall Street | 2021-11-01 07:35:49 | https://247wallst.com/healthcare-business/2021/11/01/5-big-dividend-biotech-and-pharmaceutical-stocks-have-strong-upside-potential/ | For years, one of the most dependable sectors, especially for more conservative investors, was health care, which included the top pharmaceutical and biotech stocks among other holdings. | 5 Big Dividend Biotech and Pharmaceutical Stocks Have Strong Upside Potential | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Invezz | 2021-10-30 14:58:56 | https://invezz.com/news/2021/10/30/should-i-invest-in-abbvie-shares-as-it-guides-fy2021-eps-above-street-forecast/ | On Friday, AbbVie Inc. (NYSE:ABBV) shares advanced 4.56% after announcing its fiscal third-quarter results. The company reported its most recent quarterly results before markets opened, beating analyst estimates on revenue and earnings. | Should I invest in AbbVie shares as it guides FY2021 EPS above Street forecast? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-10-29 14:38:16 | https://seekingalpha.com/article/4463602-abbvie-inc-abbv-ceo-rick-gonzalez-on-q3-2021-results-earnings-call-transcript | AbbVie Inc. (ABBV) CEO Rick Gonzalez on Q3 2021 Results - Earnings Call Transcript | AbbVie Inc. (ABBV) CEO Rick Gonzalez on Q3 2021 Results - Earnings Call Transcript | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2021-10-29 12:44:55 | https://www.benzinga.com/news/earnings/21/10/23752001/why-abbvie-shares-are-rising-today | AbbVie Inc (NYSE: ABBV) is trading higher Friday after the company announced better-than-expected third-quarter financial results and raised guidance above estimates. AbbVie reported quarterly adjusted earnings of $3.33 per share, which beat the estimate of $3.22 per share. | Why AbbVie Shares Are Rising Today | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-10-29 10:42:25 | https://www.zacks.com/stock/news/1819771/abbvie-abbv-tops-q3-earnings-estimates | AbbVie (ABBV) delivered earnings and revenue surprises of 3.10% and -0.50%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock? | AbbVie (ABBV) Tops Q3 Earnings Estimates | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2021-10-29 09:18:06 | https://www.benzinga.com/general/biotech/21/10/23742113/abbvies-major-depressive-disorder-candidate-shows-mixed-result-in-late-stage-trials | AbbVie Inc (NYSE: ABBV) has announced topline results from two Phase 3 trials, Study 3111-301-001 and Study 3111-302-001, of cariprazine (Vraylar) as an adjunctive treatment for major depressive disorder (MDD). In Study 3111-301-001, cariprazine showed a statistically significant change from baseline to week six on th... | AbbVie's Major Depressive Disorder Candidate Shows Mixed Result In Late-Stage Trials | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2021-10-29 08:04:53 | https://www.benzinga.com/general/biotech/21/10/23741410/abbvie-stock-gains-after-hiking-fy21-earnings-outlook-annual-dividend | AbbVie Inc (NYSE: ABBV) reports Q3 adjusted EPS of $3.33, higher than $2.83 reported a year ago and beating the consensus of $3.22. Overall sales increased 11.2% Y/Y to $14.34 billion, almost in line with the consensus of $14.32 billion. | AbbVie Stock Gains After Hiking FY21 Earnings Outlook, Annual Dividend | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Reuters | 2021-10-29 07:46:00 | https://www.reuters.com/article/abbvie-results/abbvie-gets-a-shot-in-the-arm-from-newer-drug-sales-lifts-profit-view-idUSKBN2HJ1I7 | U.S. drugmaker AbbVie Inc on Friday raised its 2021 adjusted profit forecast for the third time this year after a stellar performance by its newer drugs helped it beat Wall Street estimates for quarterly revenue. | AbbVie gets a shot in the arm from newer drug sales, lifts profit view | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-10-29 07:45:00 | https://seekingalpha.com/article/4462936-dividend-aristocrats-5-buys-5-avoids-october | Due to their reliability and above-average quality, Dividend Aristocrats can be great investments. One shouldn't buy at any price, however, and some of the Dividend Aristocrats look very pricy. | Dividend Aristocrats: 5 Buys And 5 Avoids For October | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-10-28 12:46:28 | https://www.fool.com/investing/2021/10/28/what-investors-should-pay-attention-to-in-abbvies/ | In a word: Humira. | What Investors Should Pay Attention to in AbbVie's Q3 Earnings Report | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-10-28 10:30:00 | https://www.fool.com/investing/2021/10/28/should-investors-worry-about-abbvie/ | AbbVie is about to lose its patent on the world's top-selling drug, but it may not be as bad as it sounds. | Should Investors Worry About AbbVie? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-10-28 09:10:00 | https://seekingalpha.com/article/4462320-bargain-alert-2-high-yield-funds-to-buy-now | Bargain Alert! 2 High Yield Funds To Buy Now | Bargain Alert! 2 High Yield Funds To Buy Now | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-10-28 07:15:00 | https://seekingalpha.com/article/4462690-abbvie-stock-fears-overblown-time-to-buy-this-high-yielder | AbbVie: Fears Are Overblown, It's Time To Buy This High-Yielder | AbbVie: Fears Are Overblown, It's Time To Buy This High-Yielder | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-10-27 12:58:36 | https://www.zacks.com/stock/news/1817615/healthcare-etfs-in-focus-as-q3-earnings-unfold | The healthcare sector is expected to witness substantial earnings growth of 17.5% in the third quarter. | Healthcare ETFs in Focus as Q3 Earnings Unfold | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-10-27 12:58:33 | https://www.zacks.com/stock/news/1817737/recovery-in-drugs-sales-to-aid-abbvie-s-abbv-q3-earnings | AbbVie (ABBV) is expected to have witnessed a recovery in demand trends of new drugs amid the receding impact of the pandemic. However, sales of physician-administered drugs are likely to have been hurt by the residual impact. | Recovery in Drugs Sales to Aid AbbVie's (ABBV) Q3 Earnings | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-10-27 07:52:00 | https://www.fool.com/investing/2021/10/27/abbvie-takes-big-step-toward-post-humira-future/ | Skyrizi is an important drug for AbbVie's future that could soon be approved for another indication in the E.U. | AbbVie Takes Another Step Toward Its Post-Humira Future | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2021-10-26 13:39:31 | https://investorplace.com/2021/10/seven-high-yield-stock-gems-for-income-obsessed-investors/ | Investors seeking big payouts should consider these seven high-yield stocks from various sectors. They range from pharmaceuticals to REITs. | 7 High-Yield Stock Gems for Income-Obsessed Investors | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-10-26 12:35:19 | https://www.zacks.com/stock/news/1816815/abbvie-abbv-to-report-q3-earnings-what-s-in-the-cards | AbbVie's (ABBV) third-quarter results are expected to reflect the impact of a strong recovery in demand for new drugs. Investors are likely to focus on any update related to guidance. | AbbVie (ABBV) to Report Q3 Earnings: What's in the Cards? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2021-10-26 10:20:38 | https://investorplace.com/2021/10/skip-jealousy-7-best-stocks-to-buy-profit-from-rich/ | With the pandemic unintuitively minting new millionaires, you can either get jealous or ride the wave with these stocks to buy. The post The 7 Best Stocks to Buy to Profit From the Rich appeared first on InvestorPlace. | The 7 Best Stocks to Buy to Profit From the Rich | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-10-26 06:45:00 | https://www.fool.com/investing/2021/10/26/was-atea-pharmaceuticals-flop-predictable/ | Were warning signs there for investors all along? | Was Atea Pharmaceutical's Flop Predictable? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-10-25 20:00:13 | https://www.zacks.com/stock/news/1816288/buy-this-great-high-yield-dividend-stock | Investors in search of stable income should consider strong dividend-paying stocks, with solid yields. Pharmaceutical standout AbbVie appears to be worth buying as a long-term play, with it set to release its Q3 results on Friday, October 29. | Buy This Great High-Yield Dividend Stock? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-10-25 19:15:37 | https://www.zacks.com/stock/news/1816224/abbvie-abbv-stock-sinks-as-market-gains-what-you-should-know | AbbVie (ABBV) closed at $108.50 in the latest trading session, marking a -0.59% move from the prior day. | AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2021-10-25 11:19:16 | https://www.benzinga.com/markets/21/10/23534196/will-chart-analysts-notice-bad-omen-on-abbvies-chart | If history is any guide, there may be trouble ahead for shares of AbbVie(NYSE:ABBV). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock. | Will Chart Analysts Notice Bad Omen on AbbVie's Chart | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
24/7 Wall Street | 2021-10-25 10:40:23 | https://feedproxy.google.com/~r/typepad/RyNm/~3/zdUiMjcxKL4/ | After years of a low interest rate environment, many investors have turned to equities not only for the growth potential but also for solid and dependable dividends, which help to provide an income stream. What this equates to is total return, which is one of the most powerful investment strategies going. | 5 Buy-Rated Blue Chips Are Raising Their Dividends This Week | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-10-25 06:39:00 | https://www.fool.com/investing/2021/10/25/what-could-these-clinical-results-mean-for-abbvies/ | The results from phase 3 clinical trials suggest that Rinvoq could be an effective treatment for patients. | What Could These Clinical Results Mean for AbbVie's Shareholders? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-10-22 16:08:28 | https://www.zacks.com/stock/news/1815363/abbvie-abbv-earnings-expected-to-grow-should-you-buy | AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. | AbbVie (ABBV) Earnings Expected to Grow: Should You Buy? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-10-22 09:30:00 | https://seekingalpha.com/article/4461241-abbvie-spotlight-on-rinvoq-a-key-element-of-mgmts-plan-to-replace-humira-sales-ahead-of-q3-results | AbbVie has grown to become a $190bn market cap pharma since it was spun out of Abbott Laboratories in 2012. Its share price is up 210% overall. The company's prime asset, Humira, will go off patent in the US in 2023. This will drop its ~$20bn annual revenues by ~20% per annum over a five-year period. | AbbVie: Spotlight On Rinvoq Ahead Of Q3 Earnings | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-10-20 22:05:12 | https://seekingalpha.com/article/4460955-3-high-yield-blue-chips-to-triple-your-retirement-income | 3 High-Yield Blue-Chips To Triple Your Retirement Income | 3 High-Yield Blue-Chips To Triple Your Retirement Income | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2021-10-20 08:36:29 | https://investorplace.com/2021/10/7-a-rated-dividend-stocks-to-buy-for-q4/ | These are among the best dividend stocks to buy for Q4. Each has an A-rating in Dividend Grader, including OMC stock and SNA stock. | 7 A-Rated Dividend Stocks to Buy for Q4 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-10-20 06:25:00 | https://www.fool.com/investing/2021/10/20/could-this-biotech-stock-be-the-next-buyout-target/ | This gene-therapy specialist may need some help turning things around. | Could This Beaten-Down Biotech Stock Be the Next Buyout Target? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2021-10-19 15:10:23 | https://www.benzinga.com/analyst-ratings/analyst-color/21/10/23443010/3-biopharma-stocks-to-watch-following-johnson-johnsons-earnings-beat | Johnson & Johnson (NYSE:JNJ) shares are higher Tuesday following the release of its third-quarter results. J&J A Bellwether For The Sector: Given the timing of J&J's earnings release and its portfolio breadth, its earnings often serve as a bellwether for the sector, according to BofA Securities analyst Geoff Meacham. | 3 Biopharma Stocks To Watch Following Johnson & Johnson's Earnings Beat | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-10-18 22:17:26 | https://www.zacks.com/stock/news/1812119/abbvie-abbv-stock-sinks-as-market-gains-what-you-should-know | AbbVie (ABBV) closed the most recent trading day at $107.43, moving -1.74% from the previous trading session. | AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2021-10-18 06:30:00 | https://investorplace.com/2021/10/7-blue-chips-to-shield-your-portfolio-from-market-downturn/ | Blue-chip stocks that have growing cash flow, good value, and have strong growth are suitable investments as the market downturn worsens. The post 7 Blue Chips to Shield Your Portfolio From Market Downturn appeared first on InvestorPlace. | 7 Blue Chips to Shield Your Portfolio From Market Downturn | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-10-16 10:45:00 | https://www.fool.com/investing/2021/10/16/3-best-dividend-stocks-for-retirement/ | These companies have positioned themselves to provide a generous and rising income stream. | 3 Best Dividend Stocks for Retirement | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-10-16 06:45:00 | https://www.fool.com/investing/2021/10/16/2-buffett-stocks-to-buy-and-hold-forever/ | The Oracle of Omaha is largely a set-and-forget kind of investor and you should be, too. | 2 Buffett Stocks to Buy and Hold Forever | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-10-15 16:03:06 | https://seekingalpha.com/article/4460143-3-buyable-dogs-bolster-buffetts-october-dividend-holdings | This Buffett holdings list from Kiplinger first appeared 8/17/21 online. YCharts and Dogs of The Dow also track this Buffett/Berkshire Batch. Here is your update from 10/13/21 YCharts data. | 3 Buyable Dogs Bolster Buffett's October Dividend Holdings | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-10-15 09:10:00 | https://seekingalpha.com/article/4459828-make-money-sleep-3-big-dividends-stocks-buy-today | For high yield hunters, market corrections are an opportunity to enhance their income stream. | Make Money In Your Sleep: 3 Big Dividends To Buy Today | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2021-10-15 08:35:00 | https://www.prnewswire.com/news-releases/abbvie-receives-chmp-positive-opinion-for-risankizumab-skyrizi-for-the-treatment-of-adults-with-active-psoriatic-arthritis-in-the-european-union-eu-301401208.html | NORTH CHICAGO, Ill., Oct. 15, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of risankizumab (SKYRIZI®, 150 mg, subcutaneous injection at week 0, week 4 and every 12 weeks thereafter) alone or ... | AbbVie Receives CHMP Positive Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Active Psoriatic Arthritis in the European Union (EU) | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-10-13 21:48:29 | https://seekingalpha.com/article/4459771-warren-buffett-loves-these-4-high-yield-dividend-aristocrats-and-so-will-you | Buffett Loves These 4 High-Yield Dividend Aristocrats And So Will You | Buffett Loves These 4 High-Yield Dividend Aristocrats And So Will You | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-10-13 09:15:00 | https://seekingalpha.com/article/4459620-abbvie-top-dividend-stock-for-long-term | AbbVie is answering the bell by building a stronger diversified portfolio for the post-Humira stage. Humira has long been the TOP selling drug in the world. | AbbVie: A Top Dividend Stock For The Long Term | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Schaeffers Research | 2021-10-12 15:04:12 | https://www.schaeffersresearch.com/content/analysis/2021/10/12/special-report-avoid-these-two-healthcare-stocks | Last month was a doozy for investors. | Special Report: Avoid These Two Healthcare Stocks | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-10-12 12:04:23 | https://seekingalpha.com/article/4459515-abbvie-dissect-sustainability-capital-allocation-like-buffett | AbbVie Inc.: Dissect Its Growth Sustainability And Capital Allocation Like Buffett | AbbVie Inc.: Dissect Its Growth Sustainability And Capital Allocation Like Buffett | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-10-12 10:58:11 | https://www.zacks.com/stock/news/1809640/3-small-biotech-stocks-in-focus-on-world-arthritis-day | Here we discuss three drugs or biotech companies with promising candidates in their pipeline for Arthritis indications. | 3 Small Biotech Stocks in Focus on World Arthritis Day | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.